(Q37836612)

24 August 2017

1 reference

title

Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance (English)

1 reference

24 August 2017

1 reference

Lana E Kandalaft

1

1 reference

24 August 2017

Gregory T Motz

series ordinal

2

1 reference

24 August 2017

Jaikumar Duraiswamy

series ordinal

3

1 reference

24 August 2017

George Coukos

series ordinal

4

1 reference

24 August 2017

1 March 2011

1 reference

Cancer and Metastasis Reviews

24 August 2017

1 reference

24 August 2017

30

1 reference

24 August 2017

141-151

1 reference

24 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-011-9289-9

24 August 2017

0 references

cites work

The management of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Systemic therapy for ovarian cancer: current status and new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Ovarian cancer creates a suppressive microenvironment to escape immune elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Tumor escape mechanism governed by myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Tumor-specific killer cells in paraneoplastic cerebellar degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Immunotherapy for gynaecological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Universal tumor antigens as targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Telomerase activity in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis o

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Natural versus adaptive regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

CD4(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Memory CD8 T-cell differentiation during viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

21 January 2018

The B7-CD28 superfamily

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The PD-1-PD-L pathway in immunological tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Restoring function in exhausted CD8 T cells during chronic viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Features of responding T cells in cancer and chronic infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Oxidized LDL activates fas-mediated endothelial cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The who, how and where of antigen presentation to B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin-1: a multifunctional molecule in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin system: the double-edged sword in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Role of Endothelin-1/Endothelin-A receptor-mediated signaling pathway in the aortic arch patterning in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The ovarian endothelin network: an evolving story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The endothelin axis: emerging role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The endothelin axis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Molecular biology and biochemistry of the endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Organization of the gene encoding the human endothelin-converting enzyme (ECE-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Expression and function of ETA and ETB receptors in SSc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Expression of CAAT enhancer binding protein beta (C/EBP beta) in cervix and endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The endothelin system in septic and endotoxin shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Effects of endothelin ETA receptor antagonism on granulocyte and lymphocyte accumulation in LPS-induced inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

A role for endothelin-2 and its receptors in breast tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Role of vascular leukocytes in ovarian cancer neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Role of endothelin in the increased vascular tone of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

Combinatorial cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9289-9

10.1007/S10555-011-9289-9

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference